The Molecular Basis of Streptococcal Toxic Shock Syndrome

New England Journal of Medicine

Volumn 350, Issue 20, 2004, Pages 2093-2094

  Brown, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBRINOGEN; INTEGRIN; M PROTEIN; VIRULENCE FACTOR; BACTERIAL ANTIGEN; CARRIER PROTEIN; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN;

ARTICLE; BACTEREMIA; COLLAPSE; HOST RESISTANCE; HUMAN; HYPERCOAGULABILITY; HYPOTENSION; NEUTROPHIL; PHARYNGITIS; PRIORITY JOURNAL; PYODERMA; SEPSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME; ANIMAL; DISEASE MODEL; LYMPHOCYTE ACTIVATION; METABOLISM; SEPTIC SHOCK;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FIBRINOGEN; LYMPHOCYTE ACTIVATION; NEUTROPHILS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 2342618763     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcibr040657     Document Type: Article

References (4)

1. Herwald H, Cramer H, Morgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004;116:367-79.
2. Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization: structural requirements, number of binding sites, and species differences. Biochemistry 1980;19:1013-9.
3. Lolis E, Bucala R. Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov 2003;2:635-45.
4. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002;30:Suppl: S214-S219.